Trials / Completed
CompletedNCT05775536
Detection of Acetylsalicylic Acid and Omega-3 Fatty Acids in Schirmers' Test Strips Using Mass Spectrometry
Detection of Acetylsalicylic Acid and Omega-3 Fatty Acids in Schirmers' Test Strips Using Mass Spectrometry and Correlations With Tear Film and Blood Flow Parameters in Healthy Adults: an Open-label Pilot Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Medical University of Vienna · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
Evaluation of tear fluid production using Schirmers' tests is a well-known and frequently used examination method in ophthalmology. Schirmers' test objectively indicates the tear fluid production over five minutes by insertion of a filter paper strip in the lower conjunctival fornix. Commonly, this method is used to quantify tear fluid production, but not tear fluid composition. The development of novel, very precise analytical methods opens up new possibilities in the use and application of Schirmers' test strips. A recently introduced analytical method is mass spectrometry. This method allows the detection and quantification of proteins, lipids, and metabolites in very low amounts of samples. Whether systemically ingested agents such as omega-3 fatty acids or acetylsalicylic acid can be detected in tear fluid using this method remains unclear. The aim of this study is to investigate the detectability of 2 different agents (acetylsalicylic acid and omega-3 fatty acids) in Schirmers' test strips from healthy subjects after intake for 1 week by use of untargeted mass spectrometry. Participating healthy subjects will receive either acetylsalicylic acid or omega-3 fatty acids.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aspirin 500Mg Tab | Dose: 1 tablet per day starting from visit 2 until visit 3, intake in the evening |
| DIETARY_SUPPLEMENT | Dr. Böhm® Omega 3 complex 870 mg | Dose: 2 tablets per day starting from visit 2 until visit 3, intake in the evening |
Timeline
- Start date
- 2021-01-21
- Primary completion
- 2021-11-30
- Completion
- 2021-11-30
- First posted
- 2023-03-20
- Last updated
- 2023-03-20
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT05775536. Inclusion in this directory is not an endorsement.